About PTC Therapeutics, Inc. - Common Stock (PTCT)
PTC Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of rare diseases and cancer. The company specializes in the development of small molecules and gene therapies that target underlying genetic causes of diseases. PTC Therapeutics aims to advance its proprietary drug candidates through clinical trials, leveraging its unique expertise in RNA biology and translational medicine. By utilizing cutting-edge technology and a collaborative approach, the company strives to bring transformative treatments to patients with unmet medical needs. Read More
PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review.
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntington's and PKU programs.
